Discovery and pharmacological characterization of novel positive allosteric modulators acting on skeletal muscle-type nicotinic acetylcholine receptors
Biochemical and Biophysical Research Communications · 2023
DOI: 10.1016/j.bbrc.2023.04.103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Asako Saito und 4 weiteren Autor:innen. Beteiligte Einrichtung: Astellas Pharma Inc, 21, Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan. Electronic address: asako.satio@astellas.com. Hauptthemen laut MEDLINE: Receptors, Nicotinic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Astellas Pharma Inc.
Abstract (Originalsprache)
Skeletal muscle-type nicotinic acetylcholine receptors (m-nAChRs) are ligand-gated ion channels that open after activation by ACh and whose signals cause muscle contraction. Defects in neurotransmission are reported in disorders such as myasthenia gravis (MG) and congenital myasthenia syndromes (CMS). Although treatments for these disorders exist, therapies which significantly increase muscle strength have yet to be reported. Positive allosteric modulators (PAMs), which promote ACh signaling through AChRs, are expected to be promising therapeutic agents. In this study, we identified an m-nAChR PAM called AS3513678 by high-throughput screening using human myotube cells and modified it to obtain novel compounds (AS3566987 and AS3580239) that showed even stronger PAM activity. AS3580239 caused a leftward shift in the ACh concentration-response curve and was 14.0-fold potent at 10 μM compared with vehicle. Next, we examined the effect of AS3580239 on electrically-induced isometric contraction of the extensor digitorum longus (EDL) muscle in wild-type (WT) and MG model rats. AS3580239 enhanced EDL muscle contraction in both WT and MG model rats at 30 μM. These data suggest that AS3580239 improved neurotransmission and enhanced muscle strength. Thus, m-nAChR PAMs may be a useful treatment for neuromuscular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Astellas Pharma Inc, 21, Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan. Electronic address: asako.satio@astellas.com.
- Astellas Pharma Inc, 21, Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan.
Förderung
- Astellas Pharma Inc
Zitieren
APA
Saito, A., Matsui, S., Chino, A., Sato, S., & Takeshita, N. (2023). Discovery and pharmacological characterization of novel positive allosteric modulators acting on skeletal muscle-type nicotinic acetylcholine receptors. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.04.103
Vancouver
Saito A, Matsui S, Chino A, Sato S, Takeshita N. Discovery and pharmacological characterization of novel positive allosteric modulators acting on skeletal muscle-type nicotinic acetylcholine receptors. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.04.103
BibTeX
@article{Saito2023,
author = {Saito, Asako and Matsui, Shigeo and Chino, Ayaka and Sato, Shota and Takeshita, Nobuaki},
title = {Discovery and pharmacological characterization of novel positive allosteric modulators acting on skeletal muscle-type nicotinic acetylcholine receptors},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
doi = {10.1016/j.bbrc.2023.04.103}
}
EUVIMED